Abstract: Provided are a multi-fluorous blockmer using a readily available fluorous tag and capable of reducing burdens of purification, and an oligonucleotide synthesis method using the same. A multi-fluorous blockmer represented by the formula is synthesized: wherein B is a natural or modified nucleobase; R1 is a protecting group that can be removed for deprotection under acidic or neutral conditions; R3 is a protecting group for phosphate; Pro is unprotected, protected, or F-protector, wherein F-protector is O(CH2)n(CF2)mCF3 when the protected moiety of nucleoside base B is O, and is NH(C?O) (CH2)n(CF2)mCF3 when the protected moiety of nucleoside base B is N, wherein n is 1 or 2 and m is an integer of 1 to 20; X is O or S; l is an integer of 0 to 58; R7 is (C?O) (CH2)2(C?O) (CH2)n(CF2)mCF3 or a silyl protecting group, wherein n is 1 or 2 and m is an integer of 1 to 20.

Abstract: An optically active segment for use in synthesis of a stereocontrolled oligonucleotide represented by the following formula (I), a method for producing the same, and a method for synthesizing a stereocontrolled oligonucleotide therefrom are provided. In formula, B is a protected/unprotected nucleoside base; R1 is substituted/unsubstituted aliphatic group; R2, R3 is a DMTr group or —P(R11)(NR12)2; R11 is OCH2CH2CN, SCH2CH2CN, etc.; R12 is a substituted/unsubstituted aliphatic group or aromatic group; X is H, an alkyl, O-alkyl, etc.; Y is H, NHR13, a halogen, etc., or a hydroxyl group protected with an acyl, ether, or silyl, or forms an X—Y bond with X; and n is an integer of 0 or more and 4 or less.

Abstract: Hyaluronic acid modified with sphingosine-1-phosphate, and a medicine comprising the hyaluronic acid as an active ingredient, wherein the medicine can alleviate hepatic disorder caused by hypoxia/reoxygenation by protecting the liver sinusoidal endothelial cells, and the medicine can prevent and/or treat liver failure due to liver transplantation, hepatectomy, or other surgeries associated with liver ischemia/reperfusion.

Abstract: A lipid membrane structure encapsulating an siRNA inside thereof and containing a lipid compound of the formula (I) as a lipid component (R1 and R2 represent CH3—(CH2)n—CH?CH—CH2—CH?CH—(CH2)m—, n represents an integer of 3 to 5, m represents an integer of 6 to 10, p represents an integer of 2 to 7, and R3 and R4 represent a C1-4 alkyl group or a C2-4 alkenyl group.

Abstract: A lipid membrane structure encapsulating an siRNA inside thereof and containing a lipid compound of the formula (I) as a lipid component (R1 and R2 represent CH3—(CH2)n—CH?CH—CH2—CH?CH—(CH2)m—, n represents an integer of 3 to 5, m represents an integer of 6 to 10, p represents an integer of 2 to 7, and R3 and R4 represent a C1-4 alkyl group or a C2-4 alkenyl group.

Abstract: Hyaluronic acid modified with sphingosine-1-phosphate, and a medicine comprising the hyaluronic acid as an active ingredient, wherein the medicine can alleviate hepatic disorder caused by hypoxia/reoxygenation by protecting the liver sinusoidal endothelial cells, and the medicine can prevent and/or treat liver failure due to liver transplantation, hepatectomy, or other surgeries associated with liver ischemia/reperfusion.